

Report 12 JAN 2005

521, 137

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
29 January 2004 (29.01.2004)

PCT

(10) International Publication Number  
WO 2004/009603 A1

(51) International Patent Classification<sup>7</sup>: C07D 495/04, 333/56, 313/12, 295/08, A61K 31/381, 31/335, A61P 35/00

(21) International Application Number: PCT/US2003/019554

(22) International Filing Date: 11 July 2003 (11.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/398,538 24 July 2002 (24.07.2002) US

(71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): WALLACE, Owen, Brendan [US/US]; 4341 Chase Circle, Zionsville, IN 46077 (US).

(74) Agents: BOUDREAUX, William, R. et al.; ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, (utility model), GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG,

[Continued on next page]

(54) Title: DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS

R<sup>4</sup>—(CH<sub>2</sub>)<sub>n</sub>—Y



(57) Abstract: The present invention provides a compound of the formula (I) wherein R<sup>1</sup> is -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), or -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl); R<sup>0</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently -H, -OH, -O(C<sub>1</sub>-C<sub>4</sub> alkyl), -OCOC<sub>6</sub>H<sub>5</sub>, -OCO(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>2</sub>-C<sub>6</sub> alkyl) or halo; R<sup>4</sup> is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3; X is -S- or -HC=CH-; G is -O-, -S-, -SO-, SO<sub>2</sub>, or -N(R<sup>5</sup>)-, wherein R<sup>5</sup> is -H or C<sub>1</sub>-C<sub>4</sub> alkyl; and Y is -O-, -S-, -NH-, -NMe-, or -CH<sub>2</sub>-; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

WO 2004/009603 A1



*PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,  
ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ,  
UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD,  
RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ,  
DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL,  
PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

— of inventorship (Rule 4.17(iv)) for US only

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*